Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets-Reference-Cited by-同舟云学术

Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets

Published:2020-12-24 Issue:1 Volume:35 Page:89-101
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Jang Minyoung,Simoens Steven^ORCID,Kwon Taeksang^ORCID

Funder

Celltrion Healthcare

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

http://link.springer.com/content/pdf/10.1007/s40259-020-00461-8.pdf

Reference65 articles.

1. Ageing Europe looking at the lives of older people in the EU: 2019 edition 2019. https://ec.europa.eu/eurostat/documents/3217494/10166544/KS-02-19%E2%80%91681-EN-N.pdf/c701972f-6b4e-b432-57d2-91898ca94893.

2. PW HMA. Europeans of retirement age: chronic diseases and economic activity. https://ec.europa.eu/2012. https://ec.europa.eu/health//sites/health/files/major_chronic_diseases/docs/rivm_report_retirement_en.pdf.

3. MacNee W, Rabinovich RA, Choudhury G. Ageing and the border between health and disease. Eur Respir J. 2014;44(5):1332.

4. Barbier L, Declerck P, Simoens S, Neven P, Vulto AG, Huys I. The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars. Br J Cancer. 2019;121(3):199–210.

5. Per Troein MN, Jyoti P, Kirstie S. The impact of biosimilar competition in Europe 2018. https://quintiles-my.sharepoint.com/personal/rgoel_in_imshealth_com/Documents/Microsoft%20Teams%20Chat%20Files/IQVIA%20Biosimilars%20EC%20Whitepaper%20ORB2731F.pdf.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An evaluation of the utilisation of biosimilar monoclonal antibody drugs in Ireland and barriers to their usage;Irish Journal of Medical Science (1971 -);2024-01-09

2. Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting;The Breast;2023-12

3. Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial;BioDrugs;2023-03-07

4. Trends in the utilization of medicines sold in the private sector post- registration in South Africa and the implications for similar countries;BMC Public Health;2023-01-28

5. Überblick über Maßnahmen zur Förderung des Einsatzes von Biosimilars in europäischen Ländern;Arzneiverordnungs-Report 2023;2023